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Background: Germ-line and sporadic mutations in the tumor suppressor gene
PTEN (also known as MMAC or TEP1), which encodes a dual-specificity
phosphatase, cause a variety of cancers such as Cowden disease,
glioblastoma, endometrial carcinoma and prostatic cancer. PTEN is widely
expressed, and Cowden disease consistently affects various organ systems,
suggesting that the PTEN protein must have an important, although as yet
poorly understood, function in cellular physiology. 
Results: Homozygous mutant mice lacking exons 3–5 of the PTEN gene
(mPTEN3–5) had severely expanded and abnormally patterned cephalic and
caudal regions at day 8.5 of gestation. Embryonic death occurred by day 9.5
and was associated with defective chorio-allantoic development. Heterozygous
mPTEN3–5 mice had an increased incidence of tumors, especially T-cell
lymphomas; γ-irradiation reduced the time lapse of tumor formation. DNA
analysis of these tumors revealed the deletion of the mPTEN gene due to loss
of heterozygosity of the wild-type allele. Tumors associated with loss of
heterozygosity in mPTEN showed elevated phosphorylation of protein kinase B
(PKB, also known as Akt kinase), thus providing a functional connection
between mPTEN and a murine proto-oncogene (c-Akt) involved in the
development of lymphomas.
Conclusions: The mPTEN gene is fundamental for embryonic development in
mice, as mPTEN3–5 mutant embryos died by day 9.5 of gestation, with patterning
defects in cephalic and caudal regions and defective placentation. Heterozygous
mice developed lymphomas associated with loss of heterozygosity of the wild-
type mPTEN allele, and tumor appearance was accelerated by γ-irradiation.
These lymphomas had high levels of activated Akt/PKB, the protein product of a
murine proto-oncogene with anti-apoptotic function, associated with thymic
lymphomas. This suggests that tumors associated with mPTEN loss of
heterozygosity may arise as a consequence of an acquired survival advantage.
We provide direct evidence of the role of mPTEN as a tumor suppressor gene in
mice, and establish the mPTEN mutant mouse as an experimental model for
investigating the role of PTEN in cancer progression.
Background
PTEN was recently cloned as a tumor suppressor gene at
chromosomal location 10q23.3 [1–3]. Somatic mutations or
homozygous deletion of PTEN have been found in various
kinds of primary malignant tumors [4], such as glioblas-
toma (20–75%) [4–6], prostatic cancer (10–49%) [7,8],
small-cell lung cancer (40%) [9], endometrial cancer
(34–50%) [10,11], breast cancer [12,13], and anaplastic
meningiomas [14]. A significantly higher rate of loss of
heterozygosity or mutations was observed in the more
advanced stage of malignant tumors (glioma, prostatic
cancer and breast cancer) [8,13,15] or in tumor cell lines
[4], suggesting that PTEN may be involved in tumor pro-
gression rather than in initiation. Germ-line mutations in
the PTEN gene cause Cowden disease [16,17], a rare auto-
somal dominant syndrome, characterized by multiple
hamartomas of the skin, intestine, breast and thyroid and
increased risk of breast, thyroid and brain tumors [18].
PTEN encodes a dual-specificity protein phosphatase
[19], and also shows homology to tensin and auxillin,
cytoskeletal proteins that interact with adhesion 
molecules. The PTEN protein has been reported to 
dephosphorylate position D3 of phosphatidylinositol
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3,4,5-trisphosphate (PtdIns(3,4,5)P3) [20], a direct product
of phosphatidyl-inositol 3′-kinase (PI3K) activity, and
PtdIns(3,4,5)P3 has been previously shown to regulate
PDK1, a kinase that phosphorylates Akt/PKB [21], the
protein product of a proto-oncogene involved in anti-
apoptotic [16,22] mechanisms. Overexpression of wild-
type PTEN suppresses growth in PTEN-mutated
glioblastoma [23]; moreover, overexpressed PTEN inter-
acts directly with focal adhesion kinase (FAK), reducing
its tyrosine phosphorylation, and eventually inhibiting cell
migration, integrin-mediated cell spreading and formation
of focal adhesions [24]. Thus, PTEN may control the
interaction between extracellular matrix and cytoskeleton,
and be involved in infiltration or metastasis of malignant
cells. The importance of an intact PTEN phosphatase
domain for its tumor suppressor function is underscored
by the finding that a large proportion of tumor-associated
PTEN mutations map to the region encoding the phos-
phatase domain [6,25]. Furthermore, phosphatase-dead
mutants are unable to reduce the tyrosine phosphoryla-
tion of FAK or reduce the PtdIns(3,4,5)P3 level and,
unlike wild-type PTEN, catalytically inactive PTEN is
unable to suppress growth and tumorigenicity of PTEN-
deficient glioblastoma cells [23]. 
To determine the role of PTEN in normal development
and tumorigenesis, we have generated mice with a tar-
geted deletion of exons 3 to 5 of the PTEN gene
(mPTEN3–5). Homozygous mPTEN3–5 mutant mice died
by embryonic day 9.5 (E9.5) and showed abnormally pat-
terned and expanded cephalic and caudal regions. Het-
erozygous mPTEN3–5 mice had a high incidence of
lymphomas associated with loss of heterozygosity of the
wild-type PTEN allele; appearance of tumors was 
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Figure 1
Targeted disruption of the mPTEN locus. 
(a) The top line shows a portion of the
mPTEN locus comprising exons 2 to 6 and
the locations of the PCR primers c and d
used to identify the wild-type allele. The
targeting vector with the neomycin-resistance
gene (neo) in antisense orientation to mPTEN
gene transcription is shown below. The
targeting vector was designed such that the
neo cassette replaced exons 3, 4 and 5 and
the splice donor site of exon 2 of mPTEN.
Diagrammed below is the targeted mPTEN
locus showing how the mutant 7 kb HindIII
fragment is created. The locations of other
restriction fragments that are diagnostic of
wild-type or mutant alleles are also shown.
The position of the 5′ flanking probe used for
genotyping by Southern analysis is shown, as
are the locations of probes 1 and 2 for loss-
of-heterozygosity (LOH) studies and the PCR
primers a and b, or e and b, which were used
to identify the mutant allele. (b) Southern blot
analysis of genomic tail DNA from one
representative litter of mPTEN3–5
heterozygous intercrosses. DNA was digested
with HindIII and hybridized with the 5′ flanking
probe (upper panel) and the neo probe (lower
panel). Using the 5′ flanking probe, a 12 kb
band representative of the wild-type allele and
a 7 kb band of the mutated allele were
detected. A single 7 kb band was obtained
using the neo probe and no random
integrations were detected. 
(c) Representative genotyping of an
embryonic litter from mPTEN3–5 heterozygous
intercross. DNA samples were subjected to
PCR using the primer pairs e/b and c/d. PCR
amplification of the wild-type mPTEN allele by
primer pair c/d yields a 669 bp fragment
(upper panel), whereas PCR amplification of
the mutated mPTEN allele by pair e/b yields a
144 bp fragment (lower panel). H, HindIII; Pv,
PvuII; Ps, PstI.
H Pv
 2
a b
5′ flanking probe 
Probe 1 for LOH
H
H
Pv H
3 4  5  6
Pv
Pv H
neo
c d
neoH Pv
Pv H
Bluescript KS+
Targeting vector
Targeted locus
H
H
Pv Pv
Pv Pv
12 kb  wild-type locus
7 kb  mutant allele
1.7 kb  wild-type locus
1.2 kb  mutant allele
Wild-type 
locus
+/–
2  6
+/– +/+ +/+ +/– +/+ +/– +/–
Wild-type 
allele
Mutant 
allele
Wild-type
 allele
Mutant 
allele
+/– +/+ +/– –/– +/– +/+ +/– +/– –/– –/–
Ps Ps
Ps
Ps Ps
Probe 2 for LOH
Ps Ps
PsPs
1.0 kb wild-type locus
1.6 kb mutant allele
neo
e
(a)
(b) (c)
Current Biology
accelerated by γ-irradiation. These tumors showed ele-
vated phosphorylation of Akt/PKB, providing a functional
connection between the murine PTEN gene and an onco-
gene involved in the development of lymphomas.
Results
Generation of mPTEN3–5 mutant mice
We disrupted the murine PTEN (mPTEN) locus by
homologous recombination in embryonic stem (ES) cells,
using a targeting vector that deleted the splice donor site
of exon 2 and the whole of exons 3 to 5, thus deleting the
phosphatase domain encoded in exon 5. A neomycin-
resistance gene (neo) with the phosphoglycerokinase
(PGK) promoter and a poly(A) addition signal was inserted
in the targeting vector in antisense orientation to mPTEN
transcription, so that the short arm of the vector consisted
of a 732 bp PCR-amplified fragment of mPTEN that
included the splice donor site of exon 2 and the long arm
contained 11.9 kb of an ApaI fragment that included
exon 6. Insertion of neo generates stop codons in all
reading frames; therefore, protein sequences beyond the
beginning of exon 6 are not expected to be translated
(Figure 1a). PCR and Southern blot analysis of ES cells
electroporated with the targeting construct showed that 6
out of 3200 G418-resistant colonies were heterozygous for
the mPTEN locus with no random integration. Three out
of six ES cell clones used to generate chimeric mice gave
germ-line transmission.
Developmental delay of E7.5 mPTEN3–5 mutant embryos
No viable homozygous mutant pups were born among 50
offspring from heterozygous intercrosses, indicating that
homozygosity for the mPTEN3–5 mutation causes embry-
onic lethality (Figure 1b). To determine the consequences
of the mPTEN3–5 mutation on embryonic development,
we analyzed embryos from heterozygous intercrosses at
different days of gestation. At E7.5, wild-type embryos
have a well-organized anteroposterior (AP) pattern and are
about to begin organogenesis (Figure 2a). In contrast, E7.5
mPTEN3–5 mutant embryos (6 embryos out of 28)
appeared less advanced, and their germ layers were not
distinct, which is characteristic of early embryonic stages
(Figure 2b). Histological analysis revealed that, whereas
normal embryos show well-defined germ layers and pri-
mordia of the headfold and allantois (Figure 2c),
mPTEN3–5 homozygous mutant embryos developed ecto-
derm and a morphologically distinct mesoderm, but
appeared more compact and less organized (Figure 2d).
The generation of mesoderm was confirmed by in situ
hybridization analysis of the expression of the early gastru-
lation marker Brachyury [26] (data not shown). Immuno-
staining with an anti-mPTEN antiserum [27] revealed
ubiquitous mPTEN expression at E7.5 (data not shown),
consistent with our northern blot analysis (see below).
Homozygous mutant mPTEN3–5 embryos showed no stain-
ing (data not shown), indicating that the mPTEN3–5 muta-
tion is very likely to be a loss-of-function mutation. 
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Figure 2
E7.5 mPTEN3–5 mutant embryos appear
developmentally delayed. (a) Wild-type
embryo, whole mount. Note the developing
headfolds in the anterior region of the embryo
(arrow). (b) mPTEN3–5 homozygous mutant
embryo. The arrow points to the poorly
organized anterior region of the embryo and
the arrowhead demarcates the junction
between the embryonic and extraembryonic
regions. (c,d) Hematoxylin and eosin staining
of (c) a wild-type and (d) a mPTEN3–5 mutant
embryo. In the wild type (c), the headfolds (hf)
are developing, the mesoderm (m) is
expanding, the allantois (al) grows in the
caudal region, and the amnion (am) is
apparent. In the mutant (d), organization is
more primitive and cephalic and caudal
structures are undefined, although the
developing mesoderm (m) is clearly visible.
(e,f) Radioactive in situ hybridization; dark-
field images showing (e) Mash2 expression in
the ectoplacental cone (arrowhead) of a wild-
type embryo and (f) expansion of Mash2
expression into the entire extraembryonic
region (arrowhead) in a mPTEN3–5 mutant
embryo, a pattern normally observed at E6.5.
Panels c–f are sagittal sections. Anterior is to
the left. Bar represents 140 µm in (a,b) and
70 µm in (c–f). 
The development of the extraembryonic lineages in
mPTEN3–5 mutants was examined by looking at the expres-
sion of Mash2, a diploid trophoblast marker [28,29]. At E7.5,
Mash2 is normally only detected in the ectoplacental cone
(Figure 2e), but mPTEN3–5 mutant embryos expressed
Mash2 in the trophoblast lineage (Figure 2f), a pattern nor-
mally observed at E6.5. Taken together, these data indicate
that early gastrulation and extraembryonic lineage specifica-
tion appear to occur normally in mPTEN3–5 mutant embryos. 
Abnormal patterning in E8.5 mPTEN3–5 mutant embryos
At E8.5, 22 out of a total of 39 (56%) mPTEN3–5 mutant
embryos analyzed were still alive and showed severe
defects in anterior and posterior development. E8.5 wild-
type embryos have by this stage undergone chorio-allantoic
fusion and have established the connection between the
maternal and embryonic circulation (Figure 3a). In con-
trast, mPTEN3–5 mutant embryos failed to connect allantois
and chorion, and instead displayed an expanded, loose and
disorganized allantois (Figure 3b). In addition, the cephalic
region also showed extremely prominent and dispropor-
tionate headfolds (Figure 3b–d). Although AP axis elonga-
tion appeared fairly normal, somites in mPTEN3–5 mutant
embryos were fewer and less distinct than in wild-type lit-
termates (Figure 3b–d). At E9.5, mPTEN3–5 mutant
embryos were dead and started to be resorbed. 
To determine if these abnormalities are the consequence
of a patterning defect, we analyzed the expression of
markers specific for these embryonic regions. Figure 3e
shows the normal striped expression of the hindbrain
marker Krox20 at E8.5 [30], and the metameric distribu-
tion of the paraxial mesoderm marker Mox1 [31]. Mutant
mPTEN3–5 embryos showed abnormal Krox20 expression
on one side of the prospective forebrain region (Figure 3f).
Mox1 was expressed in mPTEN3–5 mutant embryos
(Figure 3f), although somites appeared more compact and
less defined. Wnt1 expression is normally restricted to the
midbrain and the dorsal region of the developing neural
tube [32] (Figure 3g). In mPTEN3–5 mutant embryos, Wnt1
expression was observed in the severely deformed head
folds in the cephalic region, but not in the neural tube
(Figure 3h). The primitive-streak marker Wnt3a is nor-
mally expressed in the tail bud region [33] (Figure 3i).
Mutant mPTEN3–5 embryos showed reduced Wnt3a
expression (Figure 3j), suggesting a defect in the genera-
tion of mesodermal lineages. These results indicate that
patterning in the cephalic and caudal regions of mPTEN3–5
mutant embryos is disturbed.
Untreated or irradiated heterozygous mPTEN3–5 mice are
susceptible to tumors
Germ-line mutations at the PTEN locus are found in
Cowden disease, and affected individuals are susceptible
to hamartomas of the skin, intestine, breast and thyroid,
and are at high risk for breast cancer, thyroid cancer and
brain tumors [16]. In the mouse, northern blot analysis
revealed that in addition to being expressed throughout
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Figure 3
Abnormal patterning in E8.5 mPTEN3–5
mutant embryos. (a) Wild-type (WT) embryo.
AP pattern is well organized, and the allantois
(al) is fused to the chorion. (b–d) Mutant
mPTEN3–5 embryos. Severe overgrowths of
the cephalic region (arrowhead) and allantois
(arrow) were observed. The latter never fused
with the chorion. (e,f) In situ hybridization to
detect Krox20 (arrow) and Mox1 (arrowhead)
expression in (e) wild-type and (f) mPTEN3–5
mutant embryos. In (f), abnormal Krox20
expression was found in only one deformed
headfold; Mox1 expression in the compact
paraxial mesoderm identified the poorly
defined somites. (g,h) Wnt1 expression in (g)
the wild-type embryo is detectable in the
midbrain (arrowhead) and in the dorsal region
of the neural tube (arrow); in (h) the
mPTEN3–5 mutant embryo, Wnt1 is expressed
in the presumptive midbrain region
(arrowhead) but not in the dorsal neural tube.
The arrow in (h) points to an ectopic headfold.
(i,j) Wnt3a is strongly expressed in the tail
bud region (arrowhead) in (i) the wild-type
embryo but is reduced in the corresponding
region in (j) the mPTEN3–5 embryo. Note
hypertrophic allantois in (b–d,f,j).
Bar = 200 µm and applies to all panels.
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embryogenesis (Figure 4a), two major mPTEN transcripts
of approximately 2.5 kb and 5 kb in size are expressed in a
variety of adult tissues (Figure 4b), indicating that mPTEN
has a role in differentiated organs.
To determine whether mPTEN is a tumor suppressor gene
in the mouse, we monitored mPTEN3–5 heterozygous mice
for tumor development. In total, spontaneous tumors
occurred in 9 out of 66 (14%) heterozygous mutant mice
(Table 1). In most cases, mice were sacrificed because 
of enlargement of the cervical or axillary lymph 
nodes. Interestingly, 8 out of 9 tumors (88%) showed lym-
phoma/leukemia of the T-cell type (Figure 5a–c) as
assessed by flow cytometric analysis (Table 1). Also
observed were three cases (33%) of atypical adenomatous
hyperplasia in the liver (Figure 5d), a borderline lesion of
hepatocellular carcinoma. In addition, we observed three
cases (33%) of teratocarcinoma (Figure 5e,f), and one case
(11%) of prostatic cancer (Figure 5g). Microscopic hamar-
tomatous polyps mainly in the colon, and focal atrophic
changes in the seminiferous tubules, were observed in
most of the mice examined (data not shown). During the
period of observation, however, none of the mice devel-
oped brain tumors, thyroid cancer or breast cancer such as
seen in Cowden disease in humans. Overall, 14% of the
heterozygous mice developed tumors during the 28 weeks
of observation, whereas no tumors were observed in 50
wild-type mice during the same time. Southern blot analy-
sis using ‘probe 1’ and ‘probe 2’ (see Figure 1a) showed
either a complete or partial (due to contamination with
normal tissue) loss of wild-type mPTEN allele in two out
of eight untreated mice examined (Figure 5j). Loss of het-
erozygosity due to point mutations or small deletions was
not tested; thus the frequency of loss of heterozygosity
may be an underestimate.
Radiation-induced carcinogenesis was also examined
using 30 wild-type and 32 heterozygous mice exposed to
a single dose of 5 Gy whole-body γ-irradiation at 5–6
weeks of age and monitored for a mean of 20 weeks after
birth. Six out of 32 heterozygous mice (19%) developed
tumors in the irradiated group, whereas none of the irra-
diated wild-type mice developed tumors over the same
period (Table 1). Unlike the untreated group, tumor-
bearing irradiated heterozygous mPTEN3–5 mice were
found dead or were sacrificed because of labored breath-
ing. Autopsy revealed a markedly enlarged thymus dis-
placing the heart and lungs to the posterior of the
thoracic region. Histological analysis showed that these
tumors were thymic lymphomas/leukemias (Figure 5h,i).
Thus, irradiation significantly decreased the latency
period for tumor development (p = 0.017 by log-rank
test); moreover, all of the tumors in the irradiated group
showed loss of heterozygosity of the mPTEN locus
(Table 1), suggesting that mPTEN is one of the target
genes of radiation tumorigenesis.
Increased phosphorylation of Akt/PKB in tumors with loss
of heterozygosity at the mPTEN locus
The viral oncogene v-akt, which consists of a viral gag
sequence fused to the entire open reading frame of the
murine Akt/PKB gene, causes T-cell lymphomas in mice
[22]. We have demonstrated that mPTEN is a negative
regulator of Akt/PKB-mediated cell survival [27]; we
therefore examined the Akt/PKB phosphorylation status
in mPTEN thymomas associated with loss of heterozygos-
ity. Akt/PKB phosphorylation was greatly elevated in
these thymomas in comparison with normal thymus,
which exhibited undetectable levels of Akt/PKB phospho-
rylation (Figure 6). Thymic lymphomas associated with
mPTEN loss of heterozygosity showed reduced Akt/PKB
protein levels, possibly due to degradation or proteolytic
cleavage [34].  Thus, these thymomas may arise through
the same mechanism as those induced by AKT8, a murine
retrovirus carrying v-akt.
Discussion
Abnormal cephalic and caudal patterning in mPTEN3–5
mutant embryos
We have generated a null mutation in the mPTEN gene by
homologous recombination in ES cells. In contrast to a
recent report by Cristofano et al. [35], in which the in vitro
differentiation potential of mPTEN mutant ES cells was
analyzed, we provide an in vivo developmental characteri-
zation of the mPTEN mutant phenotype.
We found that E7.5 mPTEN3–5 mutant embryos undergo
gastrulation, although they appear less advanced and less
well organized than their wild-type littermates. At E8.5,
surviving mPTEN3–5 mutants were relatively smaller
than their wild-type littermates, and showed defective
patterning of the cephalic and caudal regions, as 
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Figure 4
The mPTEN gene is expressed throughout embryogenesis and
ubiquitously in the adult. Northern blot analysis of poly A+ RNA or
30 µg total RNA (thymus), hybridized with a full-length mPTEN cDNA
probe or with a probe for β-actin, as a control for sample loading. Two
mPTEN transcripts of 2.5 kb and 5 kb were detected in (a) embryos
and (b) adult tissues, particularly in liver and thymus.
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indicated by the abnormal expression of a number of
regionalized markers, which is accompanied by an
expansion of the neural folds and allantois. Thus, in
mPTEN3–5 mutant embryos, the excessive expansion of
the allantois may impair its fusion to the chorion, affect-
ing the process of placentation and therefore causing
embryonic death. Mutations affecting chorio-allantoic
fusion, such as VCAM1, allow embryonic survival 
until E10.5 [36,37], suggesting that impaired chorio-
allantoic fusion is not the sole cause of death of 
mPTEN3–5 mutants. Immunostaining showed that
mPTEN distribution in embryonic tissue coincided with
regions where differentiation occurs (data not shown).
Thus, death of mPTEN3–5 mutants by E9.5 is most likely
to be caused by an imbalance between growth and pat-
terning, which uncouples the timing of developmental
events in mutant embryos. Interestingly, targeted inacti-
vation of another tumor suppressor gene, Nf1, causes
lethality before E14.5, which is associated with develop-
mental abnormalities in different tissues [38,39], thus
underscoring the importance of a tight regulation of
growth and differentiation for normal development.
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Table 1
Tumors in mPTEN3–5 mutant mice.
Mouse Age (weeks) Histology Thymus Lymph Spleen Bone Liver Kidney Lung LOH
node marrow
(a) Untreated group
1 8 *Teratocarcinoma (peritoneal cavity) n.d.
Microscopic hamartomatous polyps (colon)
2 17 *Lymphoma/leukemia (T-cell) + ++ + – + + –
Atypical adenomatous hyperplasia (liver)
Microscopic hamartomatous polyps (colon)
3 17 *Lymphoma/leukemia (T-cell) ++ + + + + + +
Atypical adenomatous hyperplasia (liver)
Microscopic hamartomatous polyps (colon)
4 22 *Lymphoma/leukemia (T-cell) ++ + – – – – –
Microscopic hamartomatous polyps (colon)
5 25 *Lymphoma/leukemia (T-cell) ++ + – + –
Microscopic hamartomatous polyps (colon)
6 28 *Lymphoma/leukemia (T-cell) ++ – + + –
7 30 *Lymphoma/leukemia (T-cell) ++ + – + –
Teratocarcinoma (uterus)
Atypical adenomatous hyperplasia (liver)
Microscopic hamartomatous polyps (colon)
8 31 *Lymphoma/leukemia (T-cell) ++ + + – – + + +
Teratocarcinoma (seminiferous tubules)
Microscopic hamartomatous polyps (colon)
9 32 *Lymphoma/leukemia (T-cell) ++ + – – – – –
Prostatic cancer (well differentiated)
Microscopic hamartomatous polyps (colon)
(b) Treated with 5 Gy γ-radiation
10 16 *Lymphoma/leukemia (T-cell) ++ + + + + + +
Microscopic hamartomatous polyps (jejunum)
11 16 *Lymphoma/leukemia (T-cell) ++ + + + + + + +
12 17 *Lymphoma/leukemia (T-cell) ++ + + – + + + +
Microscopic hamartomatous polyps (colon)
13 19 *Lymphoma/leukemia (T-cell) ++ + + + + + +
Microscopic hamartomatous polyps (colon)
14 19 *Lymphoma/leukemia (T-cell) ++ + + + +
Microscopic hamartomatous polyps (colon)
15 21 *Lymphoma/leukemia (T-cell) ++ + + + + +
Microscopic hamartomatous polyps (colon)
(a) In the untreated group, 66 heterozygous and 50 wild-type mice
were observed for 20–36 weeks (mean 28 weeks). No tumors were
observed in the wild-type mice. (b) In the group treated with γ-
radiation, 32 heterozygous mice and 30 wild-type mice were observed
for 19–21 weeks (mean 20 weeks). Mice at 5–6 weeks of age were
treated with 5 Gy γ-radiation from a Cobalt 60 source at a dose rate of
1.095 Gy/min. No tumors were observed in wild-type mice. Symbols:
+, infiltration of the lymphoma cells only; ++, gross organ enlargement
and infiltration of the lymphoma cells; –, no evidence of lymphoma
infiltrate or loss of heterozygosity (LOH). An asterisk indicates the main
tumor; n.d. indicates not detected.
Our findings are very different from those of Cristofano et
al. [35] who were unable to find mPTEN mutant embryos
after E7.5 and thus did not characterize the embryonic
phenotype at all. We have deleted exons 3–5 of the
mPTEN gene, and we have shown that the mPTEN3–5
mutation is a lack-of-function mutation. Cristofano et al.
deleted exons 4–5; therefore, it is unlikely that differences
are caused by the nature of the mutations. In contrast, our
analysis was mostly made in an outbred genetic back-
ground (CD1) whereas Cristofano et al. made their studies
in an inbred background (129Sv and C57BL/J). Thus,
phenotypic differences between the two mPTEN mutants
may be attributed to the difference in genetic background. 
Loss of heterozygosity in mPTEN3–5 heterozygous mice
leads to high tumor susceptibility
Our results show that heterozygous mice are highly sus-
ceptible to tumors, especially T-cell lymphoma/leukemia,
that arise after loss of heterozygosity at the wild-type
mPTEN locus. The frequency of the PTEN mutation in
primary human lymphoma or leukemia is still unclear, but
loss of heterozygosity has been reported in 48% of
leukemia cell lines, some of which had mutations in
PTEN as well [4]. We have also observed a relatively high
incidence of teratocarcinomas in mPTEN3–5 heterozygous
mice and, although the 129 strain used in this study is
prone to develop teratocarcinomas [40], we did not detect
any teratocarcinomas in wild-type mice during the same
period of observation. We also observed one case of well-
differentiated prostatic cancer and three cases of atypical
adenomatous hyperplasia in the liver. However, glioblas-
toma, endometrial cancer, thyroid cancer and breast
cancer — in which sporadic or inherited (Cowden disease)
PTEN mutations are found — were not observed in
mPTEN3–5 heterozygous mice. The frequency of tumor-
bearing mice among mPTEN3–5 heterozygotes seems to be
much higher than in p53 heterozygotes. In the case of p53,
only 8% of heterozygous mice had tumors by 12 months of
observation [41], whereas 14% of mPTEN3–5 heterozygotes
had tumors by seven months of observation, underscoring
the importance of mPTEN in oncogenesis.
Cristofano et al. [35], have reported that mPTEN heterozy-
gotes develop glandular hyperplasia in the colon,
increased cellularity and mitotic figures in the prostatic
gland, focal acanthosis in the skin, atrophic changes in
the seminiferous tubules, and colon adenocarcinoma, 
teratoma, thyroid carcinoma and myeloid leukemia. This
tumor spectrum is different from ours, as we mainly
observe lymphomas, prostatic cancer, teratocarcinoma,
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Tumors arising in mPTEN3–5 heterozygous mice and loss of
heterozygosity in T-cell lymphomas. (a) Lymph node. Normal tissue has
been replaced by lymphoma infiltrate. (b) Kidney showing perivascular
infiltration of leukemic cells (arrow). (c,d) Liver showing (c) infiltration
of leukemic cells (arrow) and (d) atypical adenomatous hyperplasia
(arrow). (e,f) Teratocarcinoma with primitive neural component (e,
arrow). Atypical endodermal cells, blastocyst-like structures (f, arrow)
and syncytiotrophoblast giant cells were also observed. (g) Prostatic
gland showing well-differentiated carcinoma (arrow). (h,i) Thymus.
Normal tissue has been replaced by lymphoma infiltrate. Bar in (i)
represents 10 µm in (a–d,h,i); 40 µm in (e–g). (j) Loss of
heterozygosity of mPTEN in tumors. Representative Southern blots of
tumor DNA samples analyzed using the probe 1 (upper panel) and
probe 2 (lower panel; see Figure 1a). DNA was digested with PvuII
(upper panel) or PstI (lower panel). Complete loss of or a faint band of
the wild-type allele was observed in some of the lymphoma/leukemia
cases, as shown in Table 1.
hamartomatous polyps in the intestine and atrophic
changes in the seminiferous tubules. We have not
observed colon or thyroid cancers, nor myeloid leukemia,
although we have found one instance of myeloid leukemia
in heterozygous mice treated with the mutagen ethylni-
trosourea (ENU). The differences in the types of tumors
observed may be due to the following reasons. First, in our
case tumors in mPTEN heterozygous mice arise as a conse-
quence of the loss of heterozygosity of the wild-type
mPTEN allele; in the work reported by Cristofano et al.,
loss of heterozygosity at the mPTEN locus was not deter-
mined and tumors were attributed to mPTEN haplo-insu-
ficiency [35]. Furthermore, tumors were observed in
chimeric mice derived from mPTEN mutant ES cells and
in mPTEN heterozygous mice, in which only colon carci-
nomas were found [35]. Second, the periods of observation
are different, as in our case mPTEN heterozygotes were
monitored for an average of 28 weeks; in Cristofano et al.,
however, the chimeras were followed for 20 weeks, and
the heterozygotes for 8 weeks [35]. Third, the genetic
background may influence the type of tumors that origi-
nate, as in our case mPTEN heterozygous mice were
mostly of an outbred CD1 background; in Cristofano et al.
[35], the background was inbred 129Sv and C57BL/J.
The role of mPTEN in cellular survival and tumorigenesis
Our present data show that phosphorylation, and therefore
activation, of Akt/PKB is significantly elevated in tumors
generated by loss of heterozygosity at the mPTEN locus.
We have found that Akt/PKB is activated even in the
absence of stimulation in mPTEN3–5-deficient embryonic
fibroblasts, and apoptosis induced by ultraviolet (UV) radi-
ation, osmotic stimuli or tumor necrosis factor-α (TNF-α)
is inhibited in mPTEN3–5-deficient embryonic fibroblasts
[27]. Therefore, c-Akt appears to be a key target molecule
in oncogenesis mediated by loss of heterozygosity at the
wild-type mPTEN locus, as c-Akt hyperactivation may
permit mPTEN mutant cells to acquire a survival advan-
tage. Consistently, v-akt, the viral oncogene with a viral gag
sequence fused to the entire open reading frame of murine
Akt/PKB, causes T-cell lymphomas in mice [22]. Never-
theless, without testing thymic lymphomas from a differ-
ent genetic background, it is still formally possible that the
increased Akt levels observed in the thymic lymphomas of
mPTEN3–5 heterozygous mice may be an indirect effect of
transformation. During embryogenesis, enhanced Akt/PKB
activity cannot explain the phenotype observed in
mPTEN3–5 mutants, as we have not detected any reduction
in apoptosis (data not shown), suggesting that, perhaps,
alternate pathways involving PtdIns(3,4,5)P3 may exist in
the embryo.
The mPTEN gene is strongly expressed in thymus, and
most of the loss of heterozygosity that we have observed
was associated with thymic lymphomas. This would
suggest that, in mPTEN3–5 heterozygous mice, the double-
strand breaks occurring during the T-cell receptor recom-
bination process might affect the integrity of the wild-type
mPTEN locus, an effect that would be accelerated by γ-
irradiation. An alternative possibility is that, during the
recombination process, the elimination of lymphocytes
that accumulate abnormal intermediates may involve
mPTEN, acting perhaps through the inhibition of the cell
survival pathway mediated by Akt/PKB. Nevertheless, in
preliminary experiments we were unable to detect a sig-
nificant difference in irradiation-induced apoptosis
between immortalized mPTEN3–5-deficient and
mPTEN3–5 heterozygous control embryonic fibroblasts
because, under our conditions (20 Gy irradiation dose),
apoptosis was low in control cells. There may be signifi-
cant differences in thymocyte apoptosis after γ-irradiation,
however, which would be consistent with the accelerated
rate with which thymomas arise in mPTEN3–5 heterozy-
gous mice after γ-irradiation. In humans, PTEN mutations
were initially identified in glioblastomas [1]; therefore, the
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Figure 6
Increased phosphorylation of PKB/Akt in thymomas associated with
mPTEN loss of heterozygosity (LOH). Western blot analyses of whole-
cell extracts from normal mouse thymus and two thymomas
(designated thy 1 and thy 2) derived from γ-irradiated mPTEN
heterozygous mice. Antibodies used in western blots were to murine
PTEN, PKB and its phosphorylated form, and actin.
Anti-mPTEN
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question of whether mPTEN is involved in other cancers
remains open. A longer observation period of mPTEN het-
erozygotes, or the generation of T-cell-specific or brain-
specific mPTEN-deficient mice using the cre–loxP system
will solve some of these questions.
Materials and methods
Generation of mPTEN-mutant ES cells and mice
The primers used for making the short arm of the targeting construct
(see Figure 1a) were as follows: sense primer 5′-TACCGCGGGT-
TAAAGATTCTTGGCCATTAC-3′; antisense primer 5′-ATGCGGC-
CGCCTTACTACATCATCAATATTGTTC-3′. The construct was
linearized by digestion with SacII. Culture and transfection of ES cells
were as described [42]. ES cell colonies resistant to G418
(250 mg/ml; Gibco) were screened for homologous recombination by
PCR using primers specific for 5′ flanking sequences in the mPTEN
and neomycin-resistance genes (sense primer a: 5′-GCCCTACA-
GACTTTTTAATTTGTCTC-3′; antisense primer b: 5′-CAAGCAAAAC-
CAAATTAAGGGCC-3′; Figure 1a), giving an amplified fragment of
925 bp. Recombinant clones were confirmed by Southern blotting
using a 5′ flanking probe and a neomycin-specific probe to determine
that homologous recombination occurred without random integrations.
Chimeric mice were produced by microinjection using standard proce-
dures. Germ-line transmission was obtained from three independent
mutant ES cell lines that were injected into blastocysts. F2 offspring
from heterozygous intercrosses were genotyped by genomic Southern
blot (Figure 1b) or PCR analysis. The heterozygous males were
crossed with CD1 or C57BL/6J mice.
PCR analysis of mPTEN3–5 genotypes and phenotypes
Genomic DNA from ES cells and tails were isolated for PCR amplifica-
tion following published protocols [43], and amplified by PCR
(Figure 1b). Primer c (5′-ACAGACCTAGGCTACTGCTC-3′) and primer
d (5′-CTAGAAGCAAGACTTCCGTTC-3′), specific for the deleted
portion of the mPTEN gene, were used to detect the wild-type allele,
while primer e (5′-TGCTATGGGATTTCCTGCAG-3′) and primer b (see
above) were used to detect the mutant allele (Figure 1a). The PCR
cycling conditions were 50 cycles of 94°C 1 min, 64°C 1 min and 72°C
1 min. Primer pair c/d amplified a 669 bp fragment in both heterozygous
and wild-type DNA samples, whereas the primer pair e/b amplified a
144 bp fragment in both heterozygous and homozygous mutant DNA.
Histological analysis
Embryos were dissected and processed according to standard 
protocols [43].
Whole-mount in situ hybridization
E8.5 embryos were isolated in ice-cold PBS, fixed overnight in 4%
paraformaldehyde and processed for whole-mount in situ hybridization
following published procedures [44]. The probes used were Mox1
[31], Krox20 [30], Wnt1 [32] and Wnt3a [33].
Radioactive in situ hybridization
Embryos were processed as for histological analysis. The probes used
were Brachyury and Mash-2 [28]. Probes were labelled with [32P]UTP
and processed according to described protocols [45].
Analysis of tumors from mPTEN3–5 heterozygous mice
Autopsy was performed on all moribund mice or mice with visible
tumors. Specimens were fixed in 10% buffered formalin and embedded
in paraffin, or snap frozen in liquid nitrogen and stored at –70°C. For
histological analysis sections 5 µm thick were cut and stained with 
hematoxylin and eosin. Immunosurface staining from single-cell tumor
suspensions were performed according to standard methods, using
antibodies against T-cell receptor, CD4, CD8, B220, CD19 and 
Gr-1 (Pharmingen).
γ-Irradiation of mPTEN3–5 heterozygous mice
Thirty-two heterozygous, and 30 wild-type mice at 5–6 weeks of age
were exposed to a single dose of 5 Gy whole-body irradiation from a
Cobalt 60 source (Gammacell40 Exactor, Nordion International Inc.) at
a dose rate of 1.095 Gy/min.
Western blot analysis
Proteins were resolved by SDS–PAGE on 12.5% gels, electroblotted
to PVDF membrane (Boehringer Manheim), blocked in 4% skim milk,
1 × PBS, 0.05% Tween-20 and probed with primary antibodies. Anti-
PTEN [27], anti-phosphoS473 Akt/PKB and anti-Akt/ PKB antibodies
are from New England Biolabs and anti-actin antibody from Sigma. Fol-
lowing incubation with horseradish peroxidase-conjugated goat anti-
rabbit antibody (Amersham), bound immunoglobulins were detected
using enhanced chemiluminescence (Amersham).
Acknowledgements
We thank Ritsuko Yoshida, Annette van der Heiden, Christine Mirtsos, Tom
Graves, Andrew Hessel and David Siderovski for technical assistance and
helpful information; Mary Saunders and Alex Grossman for critical reading
of the manuscript and Miki Sato for her support.
References
1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al.: PTEN, a
putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
2. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et
al.: Identification of a candidate tumour suppressor gene, MMAC1,
at chromosome 10q23 3 that is mutated in multiple advanced
cancers. Nat Genet 1997, 15:356-362.
3. Li DM, Sun H: TEP1, encoded by a candidate tumor suppressor
locus, is a novel protein tyrosine phosphatase regulated by
transforming growth factor beta. Cancer Res 1997, 57:2124-2129.
4. Teng DHF, Hu R, Lin H, Davis T, Iliev D, Frye C, et al.: MMAC1/PTEN
mutations in primary tumor specimens and tumor cell lines.
Cancer Res 1997, 57:5221-5225.
5. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter
P, et al.: Mutation of the PTEN (MMAC1) tumor suppressor gene
in a subset of glioblastomas but not in meningiomas with loss of
chromosome arm 10q. Cancer Res 1998, 58:29-33.
6. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH,
Friedman HS, et al.: PTEN gene mutations are seen in high-grade
but not in low-grade gliomas. Cancer Res 1997, 57:4187-4190.
7. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM: Analysis of
PTEN and the 10q23 region in primary prostate carcinomas.
Oncogene 1998, 16:1743-1748.
8. Wang SI, Parsons R, Ittmann M: Homozygous deletion of the PTEN
tumor suppressor gene in a subset of prostate adenocarcinomas.
Clin Cancer Res 1998, 4:811-815.
9. Kohno T, Takahashi M, Manda R, Yokota J: Inactivation of the
PTEN/MMACI/ITEPI gene in human lung cancers. Genes
Chromosomes Cancer 1998, 22:152-156.
10. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al.:
Mutations in PTEN are frequent in endometrial carcinoma but rare
in other common gynecological malignancies. Cancer Res 1997,
57:3935-3940.
11. Risinger JI, Hayes AK, Berchuck A, Barrett JC: PTEN/MMAC1
mutations in endometrial cancers. Cancer Res 1997, 
57:4736-4738.
12. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J:
Mutation analysis of the putative tumor suppressor gene
PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997,
57:3657-3659.
13. Singh B, Ittmann MM, Krolewski JJ: Sporadic breast cancers exhibit
loss of heterozygosity on chromosome segment 10q23 close to
the Cowden disease locus. Genes Chromosomes Cancer 1998,
21:166-171.
14. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B,
Duerr EM, et al.: Analysis of the PTEN gene in human
meningiomas. Neuropathol Appl Neurobiol 1998, 24:3-8.
15. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et
al.: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in
multiple metastatic prostate cancer tissues. Cancer Res 1998,
58:204-209.
Research Paper  Characterization of PTEN mutant mice Suzuki et al. 1177
16. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al.:
Germline mutations of the PTEN gene in Cowden disease, an
inherited breast and thyroid cancer syndrome. Nat Genet 1997,
16:64-67.
17. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ,
Hamm H, et al.: Germline mutations in the PTEN/MMAC1 gene in
patients with Cowden disease. Hum Mol Genet 1997,
6:1383-1387.
18. Eng C: Genetics of Cowden syndrome: through the looking glass
of oncology. Int J Oncol 1998, 12:701-710.
19. Myers MP, Tonks NK: PTEN: sometimes taking it off can be better
than putting it on. Am J Hum Genet 1997, 61:1234-1238.
20. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1,
dephosphorylates the lipid second messenger,
phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998,
273:13375-13378.
21. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et
al.: Regulation of neuronal survival by the serine-threonine protein
kinase Akt. Science 1997, 275:661-5.
22. Staal SP, Hartley JW: Thymic lymphoma induction by the AKT8
murine retrovirus. J Exp Med 1988 167:1259-64.
23. Furnari FB, Lin H, Huang HJS, Cavenee WK: Growth suppression of
glioma cells by PTEN requires a functional phosphatase catalytic
domain. Proc Natl Acad Sci USA 1997, 94:12479-12484.
24. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM:
Inhibition of cell migration, spreading, and focal adhesions by
tumor suppressor PTEN. Science 1998, 280:1614-1617.
25. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z,
et al.: Mutation spectrum and genotype-phenotype analyses in
Cowden disease and Bannayan-Zonana syndrome, two
hamartoma syndromes with germline PTEN mutation. Hum Mol
Genet 1998, 7:507-515.
26. Kispert A, Herrmann BG: The Brachyury gene encodes a novel
DNA binding protein. EMBO J 1993, 12:3211-20.
27. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C,
Sasaki T, et al.: Negative regulation of PKB/Akt-dependent cell
survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
28. Guillemot F, Nagy A, Auerbach A, Rossant J, Joyner AL: Essential
role of Mash-2 in extraembryonic development. Nature 1994,
371:333-6.
29. Rossant J: Development of the extraembryonic lineages. Semin
Dev Biol 1995 6:237-247.
30. Wilkinson DG, Bhatt S, Chavrier P, Bravo R, Charnay P: Segment-
specific expression of a zinc-finger gene in the developing
nervous system of the mouse. Nature 1989, 337:461-464.
31. Candia AF, Hu J, Crosby J, Lalley PA, Noden D, Nadeau JH, Wright
CV: Mox-1 and Mox-2 define a novel homeobox gene subfamily
and are differentially expressed during early mesodermal
patterning in mouse embryos. Development 1992, 116:1123-36.
32. Wilkinson DG, Bailes JA, McMahon AP: Expression of the proto-
oncogene int-1 is restricted to specific neural cells in the
developing mouse embryo. Cell 1987, 50:79-88.
33. Takada S, Stark KL, Shea MJ, Vassileva G, McMahon JA, McMahon
AP: Wnt-3a regulates somite and tailbud formation in the mouse
embryo. Genes Dev 1994, 8:174-89.
34. Widmann C, Gibson S, Johnson GL: Caspase-dependent cleavage
of signaling proteins during apoptosis A turn-off mechanism for
anti-apoptotic signals. J Biol Chem 1998, 273:7141-7.
35. Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP: PTEN is
essential for embryonic development and tumour suppression.
Nat Genet 1998, 19:348-355.
36. Gurtner GC, Davis V, Li H, McCoy MJ, Sharpe A, Cybulsky MI:
Targeted disruption of the murine VCAM1 gene: essential role of
VCAM-1 in chorio-allantoic fusion and placentation. Genes Dev
1995, 9:1-14.
37. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA,
Labow MA: Defective development of the embryonic and
extraembryonic circulatory systems in vascular cell adhesion
molecule (VCAM-1) deficient mice. Development 1995, 
121:489-503.
38. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW,
et al.: Targeted disruption of the neurofibromatosis type-1 gene
leads to developmental abnormalities in heart and various neural
crest-derived tissues. Genes Dev 1994, 8:1019-1029.
39. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg
RA: Tumour predisposition in mice heterozygous for a targeted
mutation in Nf1. Nat Genet 1994, 7:353-361.
40. Wang D, Enders GC: Expression of a specific mouse germ cell
nuclear antigen (GCNA1) by early embryonic testicular teratoma
cells in 129/Sv-Sl/+ mice. Cancer Lett 1996, 100:31-36.
41. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A,
Donehower LA: Spontaneous and carcinogen-induced
tumorigenesis in p53-deficient mice. Nat Genet 1993, 5:225-229.
42. Suzuki A, Andrew DP, Gonzalo JA, Fukumoto M, Spellberg J,
Hashiyama M: CD34-deficient mice have reduced eosinophil
accumulation after allergen exposure and show a novel
crossreactive 90-kD protein. Blood 1996, 87:3550-3562.
43. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, et al.:
Brca2 is required for embryonic cellular proliferation in the
mouse. Genes Dev 1997, 11:1242-1252.
44. Koop KE, MacDonald LM, Lobe CG: Transcripts of Grg4, a murine
groucho-related gene, are detected in adjacent tissues to other
murine neurogenic gene homologues during embryonic
development. Mech Dev 1996, 59:73-87.
45. Hui CC, Joyner AL: A mouse model of greig cephalopolysyndactyly
syndrome: the extra-toesJ mutation contains an intragenic
deletion of the Gli3 gene. Nat Genet 1993, 3:241-246.
1178 Current Biology, Vol 8 No 21
Because Current Biology operates a ‘Continuous Publication
System’ for Research Papers, this paper has been published
on the internet before being printed. The paper can be
accessed from http://biomednet.com/cbiology/cub — for
further information, see the explanation on the contents page.
